Resverlogix Corp RVXCF

Commencement of Patient Enrollment/Dosing in Phase 2b trial

[Betteryear2]

CALGARY, Alberta, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton. The trial will evaluate the safety and efficacy of apabetalone as a potential oral treatment for COVID-19.

Apabetalone’s unique dual epigenetic mechanism may help stop disease progression by regulating the expression of disease and inflammation causing genes, without altering DNA. Through this mechanism, apabetalone has the potential to address both the viral and the more deadly inflammatory aspects of COVID-19.

“Today is a landmark moment, as patients suffering from COVID-19 are now receiving apabetalone treatment for the first time,” said Donald McCaffrey, President & CEO of Resverlogix. “Additional Canadian sites in Calgary and Toronto will soon be coming online, as well as four new sites in Brazil, that will receive apabetalone supply this week. Due to the emergence of the Omicron variant, and the speed with which it has spread, adaptations to the trial have been made to greatly expedite full enrollment. A positive outcome in this trial will enable us to move quickly to deliver apabetalone to patients in need globally, thus providing critical and affordable help in the fight against the ongoing pandemic.”

In the randomized, open-label trial, study participants will either receive twice daily oral doses of apabetalone or, alternatively, standard of care alone. A total of 100 patients are expected to be enrolled over the coming weeks, at multiple sites in Brazil and Canada. The primary outcome measure of the study will be a change in the WHO Ordinal Scale for Clinical Improvement – a standardized method of assessing COVID-19 disease severity on an 8-point scale. Secondary endpoints will include evaluating the effect of apabetalone on biomarkers of inflammation.

A summary of the study protocol can be viewed HERE.

“In addition to reducing the duration of the disease, the hope is that apabetalone will also potentially be able to protect those infected from the effects of chronic COVID-19 – often referred to as long-COVID – experienced months after the initial illness,” said Dr. Michael Sweeney, Senior Vice President, Clinical Development at Resverlogix.

https://www.globenewswire.com/news-release/2022/01/18/2368307/0/en/Resverlogix-Announces-Commencement-of-Patient-Enrollment-and-Dosing-in-a-Phase-2b-Trial-for-a-Promising-Canadian-Developed-COVID-19-Treatment.html

[seanj1]

They are going to mess up the study... as long as McCaffrey is in charge, market will not trust the company and what it says. Hence the sp lack of action..

[narmac]

Purdy well on the mark sj1,,,,,,,however if they accidentally do get good numbers in any form we might get a bump up in share price........I see a few media outlets have picked up the C19 dosing story,,,,one very important point that was not made clear to readers is that apabetalone also repairs damage to tissue from C19,,,,,,or is that NOT important and gives thie treatment a leg up on any other

[narmac]

Hummmmm,,welll,,its been 48 hours since we were first notified dosing had started with trial patients,,,,,I will assume the johnny shirts are off and the street clothes are on those not on placebo!!!  ,,,LMFAO,,,,you cant make this stuff up,,,,,I can see the expressions on the first line workers from here,,,,,,just like Lazarus!!,,more likely prayer has more effect than apabetalone with this

[seanj1]

Since this is an open label trial with short duration, if there is a positive outcome it will surely leak out and we will see that in sp and volume before any announcements from the company. I hope that the company uses any possible media attention to advertise other potential applications of Apabetalone..

[narmac]

,,,,,Hummmm........just a thought,,,,, but,,,,if there is leakage of a Lazarus effect,,,,I think we will have a chance of seeing the CUP being requested!,,,,that would be a great indication to the shareholders and the Market in general!,,Just a thought,,acchhhhh,,,,what am I thinking,,,,,I feel like I have to be on opiods just to think about something positive about RVX!!